The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.

The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

University of Auckland’s Rain Therapeutics has priced shares at $17 each to raise $125m in its initial public offering.

The oat milk brand, which has filed for a $100m offering in the US, traces its origins back to Lund University in the 1990s.

University of Louisville spinout Talaris has filed for an initial public offering on the Nasdaq Global Market.

The CIC-backed eye disease treatment developer has filed for a $100m initial public offering, having raised over $250m in funding in the past two years.